Ameliorative Effect of Chitosan Oligosaccharides on Hepatic Encephalopathy by Reshaping Gut Microbiota and Gut–Liver Axis

• DOI: 10.1021/acs.jafc.2c01330
• Publication Date: 2022-10-04T19:00:30Z
• Authors: Wei Qi; Yanyan Ge; Xinyue Wang; Zihan Li; Xiaoxue Li; Nan Wang; Hongpeng He; Xuegang Luo; Wenjian Ma; Liehuan Chen; Yihan Liu; Tongcun Zhang
• Keywords: 0301 basic medicine; Chitosan; Oligosaccharides; Thioacetamide; DNA, Ribosomal; Rats; Gastrointestinal Microbiome; 3. Good health; 03 medical and health sciences; Ammonia; Hepatic Encephalopathy; Animals; Rats, Wistar

This study investigated the influence of chitosan oligosaccharides (COSs) on a thioacetamide-induced hepatic encephalopathy (HE) Wistar rat model. COS treatment statistically reduced the false neurotransmitters and blood ammonia in HE rats, along with the suppression of oxidative stress and inflammation. The disbalanced gut microbiota was detected in HE rats by 16S rDNA sequencing, but the abundance alterations of some intestinal bacteria at either the phylum or genus level were at least partly restored by COS treatment. According to metabolomics analysis of rat feces, six metabolism pathways with the greatest response to HE were screened, several of which were remarkably reversed by COS. The altered metabolites might serve as a bridge for the alleviated HE rats treated with COS and the enhanced intestinal bacterial structure. This study provides novel guidance to develop novel food or dietary supplements to improve HE diseases due to the potential beneficial effect of COS on gut-liver axis.